{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:57:37Z","timestamp":1790873857865,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p>Chronic pain and depression diagnoses are skyrocketing. There is an urgent need for more effective treatments. Ketamine was recently established to alleviate pain and depression, but many gaps remain in the scientific literature. This paper reports the findings of an observational preliminary study that explored the efficacy of ketamine-assisted psychotherapy (KAPT) for chronic pain\/major depressive disorder (MDD) comorbidity. Researchers evaluated two KAPT approaches to determine optimal route of administration\/dose. Ten individuals diagnosed with a chronic pain disorder and MDD receiving KAPT were recruited: five individuals pursuing the psychedelic approach (high doses administered intramuscularly 24\u2005h before therapy) and five individuals pursuing the psycholytic approach (low doses administered sublingually via oral lozenges during therapy). To evaluate differences between altered states of consciousness each approach induces, participants completed the Mystical Experience Questionnaire (MEQ30) after their first (T-1), third (T-2) and sixth\/final (T-3) treatment sessions. Primary outcomes were change in Beck Depression Inventory (BDI) scores and Brief Pain Inventory (BPI) Short Form scores from baseline (T0) to (T-1)\u2013(T-3). Secondary outcomes were changes in Generalized Anxiety Disorder (GAD-7) Scale scores and Post-Traumatic Stress Disorder Checklist (PCL-5) scores at each timepoint. Statistically significant differences between each approach were not observed, but the small sample\u2019s limited statistical power makes changes seen worth noting. All participants\u2019 symptoms declined throughout treatment. Psychedelic treatment participants saw a larger, more consistent decrease. Researchers conclude that KAPT may be effective for treating chronic pain\/MDD comorbidity, anxiety and Post-Traumatic Stress Disorder (PTSD). Findings imply that the psychedelic approach may be more effective. This pilot study serves as a basis for more extensive research that will inform how clinicians administer treatment to optimize outcomes.<\/jats:p>","DOI":"10.3389\/fpain.2023.1127863","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T02:15:11Z","timestamp":1684462511000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Ketamine-assisted psychotherapy treatment of chronic pain and comorbid depression: a pilot study of two approaches"],"prefix":"10.3389","volume":"4","author":[{"given":"Daniella","family":"Batievsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari B.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Edward","family":"Thase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenick Nicholas","family":"Maglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise Christina","family":"Vidot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1215\/9780822387916","volume-title":"Global pharmaceuticals: Ethics, markets, practices","author":"Petryna","year":"2006"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2009.60.11.1439","article-title":"What did STAR*D teach US? Results from a large-scale, practical, clinical trial for patients with depression","volume":"60","author":"Gaynes","year":"2009","journal-title":"Psychiatr Serv"},{"key":"B4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamainternmed.2016.7507","article-title":"Adult utilization of psychiatric drugs and differences by sex, age, and race","volume":"177","author":"Moore","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2042098620937899","DOI":"10.1177\/2042098620937899","article-title":"Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review","volume":"11","author":"Salahudeen","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"B6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The economic burden of adults with major depressive disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jpain.2019.01.003","article-title":"Eighteen-year trends in the prevalence of, and health care use for, noncancer pain in the United States: data from the medical expenditure panel survey","volume":"20","author":"Nahin","year":"2019","journal-title":"J Pain"},{"key":"B8","article-title":"Prevalence of chronic pain increasing","volume":"67","author":"Webster","year":"2019","journal-title":"Pain News Network"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.15585\/mmwr.mm6736a2","article-title":"Prevalence of chronic pain and high-impact chronic pain among adults\u2014United States, 2016","volume":"67","author":"Dahlhamer","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/0004867416631828","article-title":"Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation","volume":"51","author":"Cusin","year":"2017","journal-title":"Aust N Z J Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejp.1153","article-title":"Ketamine for chronic non-cancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials","volume":"22","author":"Michelet","year":"2018","journal-title":"Eur J Pain"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1517\/14656566.2010.515978","article-title":"Ketamine for the treatment of chronic non-cancer pain","volume":"11","author":"Noppers","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1213\/00000539-200002000-00031","article-title":"The effects of ketamine on the temporal summation (wind-up) of the RIII nociceptive flexion reflex and pain in humans","volume":"90","author":"Guirimand","year":"2000","journal-title":"Anesth Analg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2021.100383","article-title":"Targeting inflammation in depression: ketamine as an anti-inflammatory antidepressant in psychiatric emergency","volume":"18","author":"Nikkheslat","year":"2021","journal-title":"Brain Behav Immun Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"661233","DOI":"10.3389\/fpsyt.2021.661233","article-title":"Does psychedelic therapy have a transdiagnostic action and prophylactic potential?","volume":"12","author":"Ko\u010d\u00e1rov\u00e1","year":"2021","journal-title":"Front Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221140011","article-title":"A unified model of ketamine's Dissociative and psychedelic properties","volume":"37","author":"Marguilho","year":"","journal-title":"J Psychopharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881121998321","article-title":"A qualitative and quantitative account of patient's Experiences of ketamine and its antidepressant properties","volume":"35","author":"Sumner","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ejpain.2009.09.005","article-title":"Use of oral ketamine in chronic pain management: a review","volume":"14","author":"Blonk","year":"2010","journal-title":"Eur J Pain"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1213\/01.ANE.0000086618.28845.9B","article-title":"Ketamine in chronic pain management: an evidence-based review","volume":"97","author":"Hocking","year":"2003","journal-title":"Anesth Analg"},{"key":"B23","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","article-title":"Do the dissociative side effects of ketamine mediate its antidepressant effects?","volume":"159","author":"Luckenbaugh","year":"2014","journal-title":"J Affect Disord"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1017\/S1461145713000485","article-title":"Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression","volume":"16","author":"Lara","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/AJP.0000000000000689","article-title":"Posttraumatic stress symptoms mediate the effects of trauma exposure on clinical indicators of central sensitization in patients with chronic pain","volume":"35","author":"McKernan","year":"2019","journal-title":"Clin J Pain"},{"key":"B26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pain.2009.08.015","article-title":"Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study","volume":"147","author":"Schwartzman","year":"2009","journal-title":"Pain"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcbs.2020.01.005","article-title":"Psychedelics and psychological flexibility\u2014results of a prospective web-survey using the acceptance and action questionnaire II","author":"Close","year":"2020","journal-title":"J Contextual Behav Sci"},{"key":"B28","volume-title":"Psychedelic psychiatry's brave new world","author":"Nutt","year":"2020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"643609","DOI":"10.3389\/fpsyt.2021.643609","article-title":"Comorbid chronic pain and depression: shared risk factors and differential antidepressant effectiveness","volume":"12","author":"Roughan","year":"2021","journal-title":"Front Psychiatry"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1037\/t00742-000","volume-title":"Beck depression inventory\u2013II","author":"Beck","year":"2011"},{"key":"B31","year":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/occmed\/kqt161","article-title":"The GAD-7 questionnaire","volume":"64","author":"Williams","year":"2014","journal-title":"Occup Med (Lond)"},{"key":"B33","year":""},{"key":"B34","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2023.1127863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T14:59:43Z","timestamp":1729436383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2023.1127863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":34,"alternative-id":["10.3389\/fpain.2023.1127863"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2023.1127863","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"article-number":"1127863"}}